Page 45 - Pharma Sector

Torrent Pharma acquires cosmetic derma player Curatio for Rs 2,000 cr

First major acquisition by Aman Mehta after taking charge at Torrent Pharma in August

Torrent Pharma to acquire Sequoia-backed Curatio Health for Rs 2,000 cr

Torrent Pharmaceuticals on Tuesday said it will acquire Curatio Healthcare for Rs 2,000 crore to strengthen its presence in the dermatology segment. The company has entered into definitive agreements to acquire 100 per cent of Curatio Healthcare for Rs 2,000 crore, Torrent Pharmaceuticals said in a regulatory filing. "The consideration includes Rs 115 crore (on the date of signing) of cash and cash equivalents in the acquired business indicating an enterprise value of Rs 1,885 crore," it added. The acquisition offers Torrent the opportunity to enhance its presence in dermatology with a differentiated portfolio and is a strong strategic fit, Torrent Pharmaceuticals Director Aman Mehta said. "Curatio has built a commendable set of high market share brands in cosmetic and pediatric dermatology that we look forward to adding to our product offerings," he added. Chennai-headquartered Curatio has a portfolio of over 50 brands, including Tedibar, Atogla, Spoo, B4 Nappi and Permite, in th

Prescription for recovery in FY23 for underperforming pharma sector

Easing pricing pressures, complex generics uptick in the US, steady India/emerging-market growth potential booster shots

India's Covid vaccination programme stunning: Roche's Hoffmann, Duschmale

'They (the next 125 years) look more challenging than the past 125 years. The world has changed. We have to make quicker decisions'

Growth forecast in US market set to drive gains for Cipla stock

Street remains bullish on India prospects, regulatory headwinds for Goa site continue

Indian pharma industry likely to grow to $130 bn by 2030, says IPA

The trade shows are jointly organised by Indian Pharma Machinery Manufacturers Association (IPMMA), Indian Analytical Instruments Association (IAIA) and Messe Muenchen

Core brands, new launches to help Abbott India stock outperform: Analysts

Analysts expect double-digit growth for pharma major even if Q1 disappointed

National List of Essential Medicines: All that you need to know about it

The Ministry of Health and Family Welfare released the first NLEM in 1996. It contained 279 medicines. The list was subsequently revised in 2003 and had 354 medicines

Largest Ibuprofen API maker eyes double revenue in next four years

As part of de-risking their business, they have started reducing the share of ibuprofen in their overall turnover, and add more popular products to the portfolio

Freebies to doctors: Why has the ethical code not been enforced?

Activists have been alleging nexus between pharma companies and doctors, which was echoed in the Apex Court recently. Why's Uniform Code of Pharmaceutical Marketing Practices not legally binding yet?

The New Drugs Bill: A missed opportunity for reforms in Ayush

The Bill takes regressive steps on the issue of drug safety

Centre proposes anti-dumping duty on China antibiotic drug ofloxacin

No impact on end consumer as prices are regulated

DOLO-650 makers distributed freebies worth Rs 1,000 cr to doctors: FMRAI

The petitioner, while seeking statutory backing to the Uniform Code of Pharmaceutical Marketing Practices (UCPMP), said that corruption in pharma marketing practices is yet unregulated in India

Specialty drugs may push Sun Pharma's US biz beyond $2 bn by 2025

The share of specialty medicines in overall pharmaceutical spending has been consistently increasing over the past decade, from 22 per cent in 2011 to 39 per cent in 2021

Bharat Biotech says Phase 3 trial over, intranasal vaccine 'safe'

The Hyderabad-based company claimed that BBV154 is proven to be safe, well-tolerated and immunogenic in the subjects under controlled clinical trials

Top Headlines: FPIs cut stake in BSE firms, pharma eyes $400 bn turnover

The Centre's recent move to impose GST on services rendered by the markets regulator, Securities and Exchange Board of India (Sebi), has rattled FPIs

India pharma sector exports rises 8% to $6.26 billion in first quarter

Indian pharma exports registered a growth of eight per cent during the first quarter of the current financial year to $6.26 billion, as officials hope for a 10 per cent growth by the end of the fiscal

Cipla Q1 revenue may be muted on high base, low Covid drug sales: Analysts

Cipla Q1 results preview: Analysts attribute the likely dull performance due to the high base of last year, and the reduction in revenue contribution from Covid-19 therapies in the recent quarter.

Sun Pharma's Q1 margins likely to be hit on elevated input costs: Analysts

Sun Pharma Q1FY23 results: Prabhudas Lilladher foresees the company's net profit to rise 27 per cent year-on-year (YoY) to Rs 1,786 crores from Rs 1,445 crores in the year-ago quarter.

Dr Reddy's Q1 revenue may grow up to 10% YoY, margins may expand: Analysts

Dr Reddy's Labs Q1 results preview: Analysts said that despite pricing pressures in the US, the company is likely to have recorded steady growth in this segment due to a ramp-up of new products.